Feasibility Study for Detection of Retinal Amyloid in Clinical Trials: The Anti‐Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) Trial

Alterations to the retina manifest in patients diagnosed with neurodegenerative diseases such as Alzheimer’s disease (AD). Retinal imaging techniques open the possibility for non‐invasive evaluation of AD pathology. Clinically AD diagnosed patients exhibit retinal amyloid deposits. Few studies monitoring preclinical individuals exist, limiting the assessment of the feasibility of retinal imaging as a biomarker for early‐stage AD risk detection.